Interleukin Genetics Signs Letter of Intent

Interleukin Genetics Signs Letter of Intent
Interleukin Genetics (ILGN), Wal­tham, MA, has signed a letter of intent with an undisclosed major consumer products company to develop and market proprietary genomics-based nutritional and skincare products. The two parties have executed a letter of intent that, in exchange for an undisclosed sum, permits the nutrition company a limited period in which to evaluate the option of entering into a joint venture or executing a licensing agreement in the area of nutritional genomics. The arrangement allows ILGN to continue its business development activities for the diagnostic and therapeutic applications of the company’s technology.